Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Hypothetical scenario

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon Sep 24, 2021 3:29pm

134 Views

Post# 33915233

RE:RE:RE:RE:Hypothetical scenario

Useless contribution as always mr. lingerie. Off you go to the dust bin of ignored FUD faries. Say hi to dusty, yukonjizz for brains, and 123 for me.

StockingUp21 wrote:
Muggy is the fortune teller that tells how to lose your fortune.

themagicbox wrote: Much appreciated. thanks MUGs.

MrMugsy wrote:

themagicbox wrote: Lets say Otena is done with our current indication, which I dont believe is the case at all. But as a hypothetical, given how powerful Otena is, I bet that if chronic OA doesn't work at 75mg dose, then we just re-purpose for acute pain instead of 352 to keep company alive. I see that the focus should be on 346 since its the fatherest along in the trial stages. Everything else starts at square one unfortunately.

Its a larger market and already have Phase 2B proof of concept (with that 2-week acute time horizon) that should be easily repeatable for an acute time frame. Burn rate is still under control and we have the runway to get there. It should proceed more quickly than chronic indication as well, as the chronic is a much longer time horizon.

All IMO. Food for thought.

----------------------

ahhhhhhh ... not square 1 my friend ... there is real value in what you are saying.
October first - then we get updated - we see what's available to us - negotiations out of pause ... that's what matters now.

Magic ... Supporting info/documentation re. last conversation ... on its way to you!